Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Oct 15;106(8):2837-40.
doi: 10.1182/blood-2005-04-1411. Epub 2005 Jun 23.

Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy

Morie A Gertz  1 , Martha Q Lacy, Angela Dispenzieri, Philip R Greipp, Mark R Litzow, Kimberly J Henderson, Scott A Van Wier, Greg J Ahmann, Rafael Fonseca
Affiliations

Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy

Morie A Gertz et al. Blood. .

Abstract

Fluorescence in situ hybridization (FISH) is more sensitive than conventional cytogenetics for recognizing chromosomal changes. Several FISH-detected abnormalities have been associated with inferior prognosis, including deletion of chromosomes 17 and 13 (Delta13) and t(4;14)(p16.3;q32). We analyzed the prognostic value of FISH testing in 238 patients who received high-dose therapy between January 1990 and September 2001. All patients had pretransplantation cytoplasmic immunoglobulin FISH done on cytospin slides from bone marrow aspirates for t(11;14), t(4;14), and -17(p13.1) (TP53). Time to progression and overall survival were significantly shorter for patients with t(4;14) and those with -17(p13.1) but were not affected by t(11;14). Overall survival was significantly shorter for patients with both t(4;14) and Delta13 abnormalities than for those with Delta13 alone (26.8 vs 18.8 months). In a multivariable analysis of the effect of Delta13 and t(4;14), the risk ratio for t(4;14) was greater than for Delta13 (2.6 vs 1.5). For high-dose therapy patients, -17(p13) and t(4;14) have clinical importance for estimating time to progression and overall survival. The presence of t(4;14) identifies a subset of patients whose time to progression is only 8.2 months. These patients receive minimal benefit from autologous stem cell transplantation and are candidates for novel therapeutic approaches.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Patients with and without t(11;14)(q13;q32) translocation. (A) Time to progression. (B) Overall survival. BMT indicates bone marrow transplantation.
Figure 2.
Figure 2.
Patients with and without t(4;14)(p16.3;q32) translocation. (A) Freedom from progression. (B) Overall survival. BMT indicates bone marrow transplantation.
Figure 3.
Figure 3.
-17p13.1, TP53. (A) Freedom from progression. (B) Overall survival. BMT indicates bone marrow transplantation.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Poulsen TS, Silahtaroglu AN, Gisselo CG, Tommerup N, Johnsen HE. Detection of illegitimate rearrangements within the immunoglobulin light chain loci in B cell malignancies using end sequenced probes. Leukemia. 2002;16: 2148-2155. - PubMed
    1. Garand R, Avet-Loiseau H, Accard F, Moreau P, Harousseau JL, Bataille R. t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma. Leukemia. 2003;17: 2032-2035. - PubMed
    1. Avet-Loiseau H, Garand R, Lode L, Harousseau JL, Bataille R, Intergroupe Francophone du Myelome. Translocation t(11;14)(q13;q32) is the hall-mark of IgM, IgE, and nonsecretory multiple myeloma variants. Prepublished on October 3, 2002, as DOI 10.1182/blood-2002-08-2436. - DOI - PubMed
    2. (Now available as Blood. 2003;101: 1570-1571.) - PubMed
    1. Robillard N, Avet-Loiseau H, Garand R, et al. CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. Prepublished on April 17, 2003, as DOI 10.1182/blood-2002-11-3333. ( - DOI - PubMed
    2. Now available as Blood. 2003;102: 1070-1071.) - PubMed
    1. Soverini S, Cavo M, Cellini C, et al. Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation. Prepublished on May 1, 2003, as DOI 10.1182/blood-2002-12-3789. - DOI - PubMed
    2. (Now available as Blood. 2003;102: 1588-1594.) - PubMed

Publication types

Substances